Kornimate/medical-research-clean huggingface dataset:
comparison between arthroscopic simple biceps tenotomy & anchor technique tenotomy with clinical and ultrasound assessment

Conditions: Simple Biceps Tenotomy; Anchor Tenotomy

Summary: comparison between arthroscopic simple biceps tenotomy \& anchor tenotomy technique regarding clinical outcomes \& ultrasound assessment

this research compares two surgical techniques for addressing pathologies of the long head of the biceps (lhb) tendon: arthroscopic simple biceps tenotomy and anchor tenotomy. the lhb tendon, originating from the supraglenoid tubercle, plays a critical role in forearm supination, elbow flexion, and shoulder abduction. pathologies affecting this tendon often cause significant shoulder pain, with surgical options including tenotomy and tenodesis. while simple tenotomy is quick and avoids implant complications, it may result in cosmetic deformities like the "popeye" sign and muscle cramps. anchor tenotomy, a novel technique, aims to minimize these issues by preventing the popeye deformity. this study employs a prospective randomized double-blinded controlled trial design at assiut university hospitals, involving 72 patients with lhb pathologies such as tendinitis, rotator cuff tears, and subacromial impingement. exclusion criteria include prior tenodesis or neuromuscular diseases. clinical outcomes will be assessed using functional scores (e.g., oxford shoulder score), ultrasound evaluation of tendon positioning, and follow-up examinations at intervals up to one year post-surgery. the primary outcome focuses on the presence of the popeye deformity, while secondary outcomes include postoperative shoulder function and tendon distalization measured via ultrasound. this research aims to provide evidence-based insights into the comparative effectiveness of these two techniques in improving clinical outcomes and minimizing complications.

Eligibility criteria:
inclusion criteria: * patients with lhb pathologies such as : biceps tendinitis rotator cuff tears subacromial impengiment instability \& traumatic causes exclusion criteria: * lhb tenodesis patients with neuromuscular disease

Keywords: arthroscopic biceps tenotomy long head of biceps tendon (lhb) popeye deformity ultrasound assessment
effect of a traditional chinese medicine formulation on covid-19 infection

Conditions: COVID-19

Summary: traditional chinese medicine (tcm) has been handed down for thousands of years. it has a long history in the treatment of virus infection and has a good effect on the upper respiratory tract infection. in recent years, the project applicant has been conducting research on the anti infection and anti inflammation treatment of traditional chinese medicine, and has carried out a lot of clinical practice exploration in non-specific inflammation. the purpose of this research is to study the therapeutic effect of a traditional chinese medicine prescription on covid-19 infection.


Eligibility criteria:
inclusion criteria: * in the past two to three days, covid-19 test was positive, accompanied by more than one clinical symptom. * 18 ≤ age ≤ 65, regardless of gender; * patients have good follow-up compliance. exclusion criteria: * human immunodeficiency virus - 1 infection and malignant tumors; active cardiovascular, kidney, lung, liver, blood, digestive, neurological or psychiatric diseases; recent acute respiratory symptoms (within 4 weeks) . * any drug that may interfere with the evaluation (for example, other herbal products such as lianhua qingwen, immunosuppressants, anticoagulants), or a history of allergy or other adverse reactions to traditional chinese medicine products. * pregnant or lactating women. * allergic constitution and allergy to multiple drugs. * according to the judgment of the investigator, the subject suffers from any disease that may endanger his safety or affect his compliance with the protocol, or other conditions that are not suitable for the study.
dalpiciclib in combination with exemestane and trastuzumab plus pyrotinib in early triple positive breast cancer

Conditions: Breast Cancer; Estrogen Receptor Positive Tumor; HER2-positive Breast Cancer

Summary: this is a phase ii open-label, multicenter trial assessing the efficacy of combination regimen"dalpiciclib plus exemestane plus trastuzumab plus pyrotinib"in early triple positive breast cancer patients.

this is a phase ii open-label, multicenter trial. the study assesses the treatment of patients with er-positive /her2 positive early breast cancer with neoadjuvant dalpiciclib in combination with exemestane and trastuzumab plus pyrotinib. patients were treated with intravenous trastuzumab (8 mg/kg loading dose followed by 6 mg/kg, q3w) for six cycles plus oral dalpiciclib (125 mg qd x 21，q4w) and exemestane (25 mg po qd ）and oral pyrotinib (320 mg po qd) for 20 weeks. the primary endpoints was pathological complete response.

Eligibility criteria:
inclusion criteria: * 18 years to 75 years * newly diagnosed clinical stage ii or iii er+/her2+ breast cancer, staging criteria is to be based on ajcc 7. * eastern cooperative oncology group (ecog) performance status 0 or 1 * primary tumor must have positive estrogen receptor (er) ≥10% * primary tumor must be her2-positive (ihc 3+ or fish/cish amplification) * baseline lvef ≥50% measured by echocardiography (preferred) or muga scan * normal organ and marrow function * written informed consent (ic) must be signed and dated by the patient and the investigator prior to randomization. * baseline corrected qt interval (qtcf) \< 480 ms * all patients must be female. exclusion criteria: * inflammatory breast cancer * evidence of bilateral invasive breast cancer or metastatic disease * received any prior treatment for primary invasive breast cancer * pregnant or lactating women * abnormal baseline hematological values: * abnormal baseline liver function, bilirubin, creatinine and/or inr (international normalized ratio) * subjects with known infection with hiv, hbv, hcv * other investigational drugs while on study * severe or uncontrolled hypertension, history of congestive heart failure or severe coronary arterial disease. * subjects assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol
treatment of phimosis with topical steroid cream -double-blind, randomized, placebo-controlled study

Conditions: Phimosis

Summary: during last years topical steroid creams have been suggested to be effective treatment for non-retractable foreskin instead of circumcision. aim of this study is to investigate the efficacy, safety and persistence of treatment results of a medium potent steroid cream in a double-blind, randomized, placebo-controlled study.


Eligibility criteria:
inclusion criteria: * non-retractable foreskin requiring treatment exclusion criteria: * age under six years old, previous operation or steroid treatment for phimosis

Keywords: phimosis, non-retractable foreskin topical steroids children
a study of the intestinal microbiome in patients with cirrhosis

Conditions: Liver Cirrhosis

Summary: this study aims to establish a cohort for analyzing the gut microbiome of patients with liver cirrhosis and to identify factors that influence the prognosis of these patients.


Eligibility criteria:
inclusion criteria: 1. aged 19 years or older: 2. patients visiting the hospital with liver cirrhosis. 3. patients diagnosed with liver cirrhosis who can understand the information provided to them or their representatives and have voluntarily given written consent to participate in this study exclusion criteria: 1. cases not meeting the inclusion criteria 2. patients who refuse participation 3. patients who have taken or been administered antibiotics within the past 2 weeks or are scheduled to take or receive antibiotics during the study period 4. cases where the diagnosis is unclear 5. cases with incomplete data or missing investigation items 6. individuals deemed unsuitable by the principal investigator for other reasons

Keywords: liver cirrhosis
open-label study of oto-201 for middle ear effusion evaluating trans-tympanostomy tube administration

Conditions: Bilateral Middle Ear Effusion

Summary: this is a 1-month, prospective, multicenter, open-label study in pediatric subjects with bilateral middle ear effusion requiring tympanostomy tube placement. eligible subjects will receive a single dose to each ear of 6 mg oto-201, administered intraoperatively into the middle ear through the lumen of the tympanostomy tube (trans-tympanostomy tube ttt). the study is designed to characterize safety and any procedural issues associated with ttt drug administration of oto-201.


Eligibility criteria:
inclusion criteria includes, but is not limited to: * subject is a male or female aged 6 months to 17 years, inclusive * subject has a clinical diagnosis of bilateral middle ear effusion requiring tympanostomy tube placement * subject's caregiver is willing to comply with the protocol an attend all study visits exclusion criteria includes, but is not limited to: * subject has a history of prior ear or mastoid surgery, not including myringotomy or myringotomy with tympanostomy tube placement * subject has a history of sensorineural hearing loss * subject has been designated for any other surgical procedure that would occur concurrently with tt placement, such as, but not limited to adenoidectomy or tonsillectomy
is this pji really acute: a quantitative sonication fluid analysis (sonic)

Conditions: Prosthetic-joint Infection

Summary: this retrospective study is to analyse microbiological cultures from the sonication fluid of the explanted prothesis to detect bacteria in the biofilm on the implant surface and to investigate whether the number of bacteria in the biofilm correlates with the duration of the pji respectively with the period between symptom onset and date of revision surgery.

implant associated infections in orthopaedics and trauma surgery are a well-known and feared complication. prosthetic-joint infection (pji) is caused by a biofilm which is located atop the surface of the implant which as growing with the duration of the pji. this retrospective study is to analyse microbiological cultures from the sonication fluid of the explanted prothesis to detect bacteria in the biofilm on the implant surface and to investigate whether the number of bacteria in the biofilm correlates with the duration of the pji respectively with the period between symptom onset and date of revision surgery.

Eligibility criteria:
inclusion criteria: * patients who underwent a revision surgery of hip, knee and shoulder arthroplasties operated at the university hospital of basel between 2011 and 2021, * patients who had a pji as a suspected diagnosis and * have microbiological cultures from sonication fluid from removed prosthesis. exclusion criteria: * patients in the database who 1. have non-bacterial microbiological positive cultures (e.g. fungal infection) and 2. have not received a sonication of the removed prosthesis during the diagnostic process

Keywords: debridement, antibiotics and implant retention (dair) sonication fluid analysis
single incision versus conventional 3-port laparoscopic appendectomy

Conditions: Appendicitis

Summary: a randomized trial to study the null hypothesis:" single incision appendectomy does not take longer operation time when compared to conventional 3-port appendectomy". the study will be carried out in a tertiary referral center in hong kong with a catchment population of 1 million.

since the introduction of single incision laparoscopic surgery (sils), this approach has become more popular and various case series and reports had described its feasibility in many general surgical procedures including appendectomy, cholecystectomy, and colectomy. despite this, strong evidence in support of sils to be equivalent or even superior to conventional multi-port approaches remain scarce, although there are case series and comparative studies with promising results in cholecystectomy and colectomy. there are many case series available stating that single incision appendectomy may be a feasible alternative to conventional approach, but may be at the expense of a longer operating time and a higher post operative wound pain score. a recent randomized trial by st. peter et al. was the first to test the feasibility of this approach to standard 3-port approach in appendectomy in children. under randomized settings of this trial the single incision appendectomy produced longer operating times and resulted in greater charges. however, the primary outcome measure in this trial was wound infection and the result showed no significant differences between the two approaches. the answer to whether single incision appendectomy produces a longer operating time when compared to conventional 3-port approach remained undetermined, in particular the adult population, and therefore a randomized trial design based on operating time as its primary outcome is desired.

Eligibility criteria:
inclusion criteria: * appendicitis score \>5, imaging showed no complication from appendicitis exclusion criteria: * pregnancy, mentally incapacitated, previous surgery
a head-to-head comparison of [68ga]ga-fapi and [68ga]ga-tate pet/ct in patients with nasopharyngeal carcinoma: a single-center, prospective study

Conditions: Tumor Positron-Emission Tomography

Summary: both fibroblast activation protein (fap)-targeted imaging and somatostatin receptors (sstr)-targeted imaging were the promising imaging modalities for the diagnosis of primary and metastatic nasopharyngeal carcinoma (npc). this prospective study is going to investigate to compare the diagnostic efficacy of 68ga-fapi and 68ga-dotatate in detecting primary and metastatic npc lesions, thereby obtaining a more accurate examination method of npc.

patients with newly diagnosed or previously treated npc will be recruited in this study. each patient received an intravenous injection of 68ga-dotatate (2-4mci) on the first day and 68ga-fapi (2-4mci) on the second day. whole-body pet/ct scans were performed at 40-60 min after injection on the same scanner. physiologic normal-organ uptake, lesion numbers, and lesion uptake were compared.

Eligibility criteria:
inclusion criteria: * patients of either gender, aged ≥ 18 years. * patients with newly diagnosed or previously treated npc * a diagnostic magnetic resonance imaging (mri) of the tumor region within the previous 1 weeks prior to dosing day is available. * signed written consent. exclusion criteria: * pregnancy * breastfeeding * the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.
effect of azithromycin on fatty acids in cf

Conditions: Cystic Fibrosis

Summary: in collaboration with dr.birgit alteheld, institute of nutrional sciences of the university of bonn, germany the following effect is explored: effect of a 4 week therapy with azt on synthesis of lipoproteins as well as docosahexaen and other fatty acids in patients with cystic fibrosis (cf). moreover proinflammatory cytokines in blood and sputum are of interest.

the macrolide azithromycin (azt) is recommended by flume in the cf pulmonary guidelines for long-term treatment of patients with cf chronically colonized with pseudomonas aeruginosa due to its immunomodulating properties . azt causes a significant reduction of the proinflammatory cytokine lipopolysaccharid binding protein (lbp) according to steinkamp and schmitt-grohé. there is an inverse correlation between lbp and lung function. moreover schmitt-grohé and coworkers provided evidence of a positive correlation between the lipoprotein hdl and lung function. ribeiro and coworkers found an increased expression of lipid/cholesterol genes of primary human airway epithelial cultures after treatment with azt. freedman and coworkers were able to show decreased levels of docosahexaen acid in cf patients. the aim of this study is to explore the impact of a 4 week trial of azt on lipoprotein and fatty acids (docosahexaen acid etc.) synthesis. delta f508 homozygous patients receive azt (10 mg/kg body weight resp. max 500 mg) every monday, wednesday and friday for 4 weeks. 20 patients (age 10-60 years) will be recruited. fatty acids (blood), cytokines (whole blood and induced sputum) and clinical parameters are assessed before and 4 weeks after azt treatment.

Eligibility criteria:
inclusion criteria: * delta 508 homozygous and regularly visiting the cf outpatient clinic bonn exclusion criteria: * clinical or laboratory signs (crp \> 20 mg/l) of an exacerbation, * treatment with systemic steroids 14 days preceeding this trial * elevated liver function tests (\> twice normal range)

Keywords: cystic fibrosis
frequency of correct response and factors associated in the medium term with a multimodal rehabilitation program for chronic low back pain

Conditions: Chronic Low-back Pain

Summary: non-specific chronic low back pain is defined as pain that originates in the lumbar spine, is persistent, lasts more than 3 months, and is unrelated to an inflammatory, traumatic, tumour, malformation, or infectious cause. chronic low back pain is one of the most frequent reasons for consulting a physician, and one of the most common sources of disability, particularly as a result of socio-professional withdrawl. it is a major consumer of health resources (diagnostic investigations, multiple treatments) and involves heavy expenses for the investigator's health insurance system. in view of this major public health issue, in november 2017, the health insurance and several specialized health organizations launched a "general public" campaign to raise awareness of low back pain. this campaign, entitled "back pain? the right treatment is movement" was designed to encourage appropriate physical activity in patients with low back pain. among the available therapies, multimodal programs are recommended as a first line treatment. in order to incorporate physical activity into patients' daily lives, these rehabilitation programs are based on a comprehensive multidisciplinary approach (therapeutic education, muscle strengthening, reconditioning, ergonomics, psychological, social, professional and nutritional management and cardiovascular risk factors). although such programmes have already shown short term effectiveness, few data are available on their continued effectiveness in the medium term (1 year). this project aims to identify good and bad responders to a multimodal program in the medium term, based on common clinical parameters (quebec city questionnaire score and spontaneous walking speed), and to identify the mechanisms underlying this response. in addition, in clinical practice, heterogeneity in maintaining the effectiveness of the program is observed but little documented. the limited data available show a heterogeneity of these programs and one of the objectives of this project will be to identify the existing barriers and levers available to improve this situation.


Eligibility criteria:
inclusion criteria: * adult patient * having provided oral consent * chronic non-specific low back pain (has2015 criteria) * eligible for a rehabilitation program * patient affiliated or benefiting from a social security scheme exclusion criteria: * adult unable to provide consent * lumbar spine surgery scheduled in the coming year * associated pathologies other than spinal (orthopedic, neurological, vascular, cardiac...) that can affect locomotion * root damage with motor deficit \<3 * altered comprehension skills making self-assessment impossible * patient subject to a protective measure (guardianship, curatorship) * patient subject to a judicial protection * pregnant, parturient or breastfeeding woman * not fluent in french * patient who has already completed a multimodal rehabilitation program
enhanced external counterpulsation and its effects on vascular hemodynamics in cognitively impaired patients

Conditions: Mild Cognitive Impairment

Summary: the aim of this study is to investigate whether enhanced external counterpulsation (eecp) therapy for 7 consecutive weeks will improve cerebral blood flow and possibly over time enhance or slow down breakdown of cognitive function in patients diagnosed with mild cognitive impairment (mci).


Eligibility criteria:
inclusion criteria: * an adult between 18 and 85 years of age. * has been evaluated to have a cdr (clinical dementia rating) score of 0.5 * male or female (if female must be postmenopausal for at least 1 year, surgically sterile or using an effective form of contraception). * able to speak and read english. * willing to comply with study specific instructions, and complete all study procedures according to protocol. * able to understand study rationale and sign informed consent. exclusion criteria: * diagnosed with glaucoma * history of developing adverse effects to ophthalmic dilating agents (phenylephrine or tropicamide). * currently taking warfarin and dabigatran (pradaxa). * history of having arrhythmias - can interfere with eecp triggering. * subject has bleeding diathesis. * subject has active thrombophlebitis. * subject has severe lower extremity vaso-occlusive disease. * subject has a documented aortic aneurysm requiring surgical repair. * subject is pregnant. * subject with blood pressure higher than 180/110 mmhg. * subject with a heart rate more than 120 bpm. * subject with high risk of complications from increased venous return. * subject with clinically significant valvular disease. * subjects with severe vascular disease as established by the hachinski ischemic index. * subjects with pacemakers and other metallic implantable devices.

Keywords: alzheimer's disease cerebral blood flow ophthalmic blood flow blood viscosity
fractalkine, a cx3c chemokine, act as a mediator of ocular angiogenesis

Conditions: Proliferative Diabetic Retinopathy; Angiogenesis

Summary: fractalkine (fkn) is a chemoattractant and adhesion molecule for leukocytes. angiogenic effect of fkn also has been reported. we investigate fkn-mediated angiogenesis in ocular angiogenic disorders.

fractalkine (fkn), the sole member of the cx3c chemokine family, is named for its fractal geometry. the cx3c motif, with three amino acids between the two terminal cysteines, makes fractalkine distinct from other chemokines.the structure of fractalkine, a membrane-bound glycoprotein with the chemokines domain atop an extended mucin-like stalk, also is unique.membrane-bound fkn can be markedly induced on primary endothelial cells by inflammatory cytokines; this form promotes the robust adhesion of monocytes and t lymphocytes. soluble fkn can be released by proteolysis at an efficient chemotactic activity level for monocytes and t cells. thus, fkn is a versatile molecule regulating both cell-cell interactions in its membrane-bound form and directed-cell migration in its soluble form. the receptor of fkn, cxc3r1, is a g protein-couple protein, which expresses t lymphocytes, monocytes, natural killer (nk) cells, microglia, and neurons.sulfation of tyrosine enhances the function of cx3cr1 in cell capture and firm adhesion. fractalkine is expressed constitutively in the kidney, heart, lung, and brain. fractalkine has demonstrated an important role in cns inflammation, cardiac allograft rejection, arteriogenesis, renal disease, psoriasis, and during pregnancy. silverman et al demonstrated the presence of fkn in normal cultured microvascular endothelial and stromal cells of iris and retina in vitro. upon inflammatory cytokine stimulation, ec also express fkn and its receptors with fkn secretion in an autocrine manner. in addition to ec chemotaxis and tube formation, fkn is an angiogenic mediator in rheumatoid arthritis. therefore, we hypothesize that fkn not only participates in ocular inflammatory reactions, but also plays an important role in ocular angiogenesis.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of proliferative diabetic retinopathy. * who will receive vitrectomy for treatment of disease. exclusion criteria: * previous ocular surgical history. * history of uveitis * history of ocular trauma.

Keywords: proliferative diabetic retinopathy angiogenesis vitreous levels vascular endothelial growth factor fractalkine growth factor